NCT00428337View on ClinicalTrials.gov

Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 30, 2007

Study Completion Date

August 31, 2008

Conditions
HIV Infections
Interventions
BIOLOGICAL

EP-1233

DNA-HIV-recombinant vaccine

BIOLOGICAL

MVA-mBN32

HIV-recombinant viral vaccine

Trial Locations (3)

14642

Univ. of Rochester HVTN CRS, Rochester

37232

Vanderbilt Vaccine CRS, Nashville

94102

San Francisco Vaccine and Prevention CRS, San Francisco

Sponsors

Collaborators (1)

Bavarian Nordic
All Listed Sponsors
collaborator

HIV Vaccine Trials Network

NETWORK

collaborator

Pharmexa-Epimmune

UNKNOWN

collaborator

Bavarian Nordic

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH